A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01413178

Recruitment Status : Completed

First Posted : August 10, 2011

Results First Posted : April 21, 2020

Last Update Posted : April 21, 2020

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Information provided by (Responsible Party):

M.D. Anderson Cancer Center

Study Description

Brief Summary:

The goal of this clinical research study is to compare Busulfex (busulfan) with or without Alkeran (melphalan) to learn which study therapy may be better at helping to control MM in patients who will receive an autologous stem cell transplant. The safety of this combination therapy will also be studied.

Melphalan and busulfan are designed to damage the DNA (genetic material) of cells, which may cause cancer cells to die.

Condition or disease	Intervention/treatment	Phase
Myeloma	Drug: Busulfan Drug: Melphalan Other: Questionnaire Drug: G-CSF Drug: High Dose Melphalan Procedure: Stem cell transplant	Phase 3

Show detailed description

Detailed Description:

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups.

Group 1 will receive melphalan and busulfan.
Group 2 will receive melphalan.

Both groups will have a stem cell transplant.

Study Drug Administration:

If you are in Group 1, you will first receive an additional low-level "test" dose of busulfan given by vein to check how your blood levels change over time. This information will be used to decide the next dose that is needed to reach a target blood level of busulfan. Blood (about 1 teaspoon each time) will be drawn up to 11 times during the next 11 hours after the test dose and the first high-dose busulfan treatment.

A heparin lock line will be placed in a vein to lower the number of needle sticks needed for these draws.

This test dose of busulfan can be given as an outpatient before you are admitted to the hospital, or you will be admitted on Day -10 (10 days before your transplant) and will receive the test dose on Day -9. If it is not possible for these blood level tests to be performed for technical or scheduling reasons, you will receive the standard, fixed (unchanging) dose of busulfan.

Eight (8) or 10 days before the transplant, you will be admitted to the hospital and given hydration fluids by vein.

On Days -7, -6, -5, and -4, you will receive busulfan by vein over 3 hours. You will receive melphalan on Days -2 and -1 by vein over 30 minutes. You will receive the stem cell transplant through the CVC on Day 0.

If you are in Group 2, you may be admitted to the hospital 3 days before the transplant. You will receive hydration fluids by vein. Two (2) days before the transplant, you will receive melphalan by vein over 30 minutes. You will not receive melphalan the day before the transplant.

Stem Cell Transplant:

The day that you receive the stem cell transplant is called Day 0. The stem cells will be given by vein through the CVC. The cells will travel to your bone marrow where they are designed to start making healthy, new blood cells after several weeks. You will sign a separate consent for the collection of your stem cells.

Beginning 5 days after the transplant, you will receive filgrastim (G-CSF) through a needle under your skin 1 time each day until your blood cell levels return to normal. Filgrastim is designed to help with the growth of white blood cells.

You will be in the hospital after the transplant for about 2-4 weeks.

Questionnaire:

You will be asked to complete a quality-of-life questionnaire before starting the study drugs and then once a week during Weeks 1, 2, and 4 after the stem cell transplant. The questionnaire will take about 15 minutes to complete.

Follow-Up Visits:

About 3 months after the transplant, you will have a bone marrow aspiration and biopsy to check the status of the disease. To collect a bone marrow aspiration and biopsy, an area of the hip is numbed with anesthetic, and a small amount of bone marrow and bone is withdrawn through a large needle.

Every 3 months during the first year after the transplant, blood (about 1-2 tablespoons) will be drawn to check your immune response and status of the disease.

About 1 year after the transplant, you will have a bone scan if the doctor thinks it is needed.

Length of Study:

One (1) year after the transplant, your participation in this study will be over.

If intolerable side effects from the chemotherapy occur or there is sign of disease after the transplant, you will be taken off study. If you have intolerable side effects after you receive chemotherapy, then you will still have the transplant. If you are taken off study early, you still may need to return for routine post-transplant follow-up visits, if your transplant doctor decides it is needed.

This is an investigational study. Busulfan and melphalan are commercially available and FDA approved for the treatment of myeloma. The use of melphalan alone before an autologous stem cell transplant is considered standard of care. Using busulfan with melphalan is investigational.

Up to 205 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	205 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Actual Study Start Date :	September 30, 2011
Actual Primary Completion Date :	March 10, 2019
Actual Study Completion Date :	March 10, 2019

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Multiple myeloma

MedlinePlus related topics: Multiple Myeloma

Drug Information available for: Busulfan Melphalan Melphalan hydrochloride

Genetic and Rare Diseases Information Center resources: Multiple Myeloma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Busulfan + Melphalan Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.	Drug: Busulfan Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4. Other Names: Busulfex Myleran Drug: Melphalan 70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1. Other Name: Alkeran Other: Questionnaire Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete. Other Name: Survey Drug: G-CSF Approximately 5 mcg/kg/day subcutaneously beginning on Day +5. Other Names: Filgrastim NeupogenTM Procedure: Stem cell transplant Stem cell infusion on Day 0. Other Names: ABMT autologous bone marrow transplantation Peripheral Blood Progenitor Cells PBPCs
Experimental: Melphalan High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.	Other: Questionnaire Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete. Other Name: Survey Drug: G-CSF Approximately 5 mcg/kg/day subcutaneously beginning on Day +5. Other Names: Filgrastim NeupogenTM Drug: High Dose Melphalan 200 mg/m2 by vein over 30 minutes on Day -2. Other Name: Alkeran Procedure: Stem cell transplant Stem cell infusion on Day 0. Other Names: ABMT autologous bone marrow transplantation Peripheral Blood Progenitor Cells PBPCs

Arm

Intervention/treatment

Experimental: Busulfan + Melphalan

Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.

Drug: Busulfan

Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.

Other Names:

Busulfex
Myleran

Drug: Melphalan

70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.

Other Name: Alkeran

Other: Questionnaire

Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.

Other Name: Survey

Drug: G-CSF

Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.

Other Names:

Filgrastim
NeupogenTM

Procedure: Stem cell transplant

Stem cell infusion on Day 0.

Other Names:

ABMT
autologous bone marrow transplantation
Peripheral Blood Progenitor Cells
PBPCs

Experimental: Melphalan

High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.

Other: Questionnaire

Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.

Other Name: Survey

Drug: G-CSF

Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.

Other Names:

Filgrastim
NeupogenTM

Drug: High Dose Melphalan

200 mg/m2 by vein over 30 minutes on Day -2.

Other Name: Alkeran

Procedure: Stem cell transplant

Stem cell infusion on Day 0.

Other Names:

ABMT
autologous bone marrow transplantation
Peripheral Blood Progenitor Cells
PBPCs

Outcome Measures

Primary Outcome Measures :

Progression-Free Survival (PFS) [ Time Frame: 3 years after transplant ]
Participants that are still alive and without Multiple Myeloma 3 years after Stem cell Transplantation.

Secondary Outcome Measures :

Number of Participants With Complete Response (CR) [ Time Frame: Evaluated 90 days from transplant. ]
Complete response (CR), evaluated 90 days from transplant, defined as (i) negative immunofixation of the multiple myeloma (MM) protein in urine and serum, (ii) disappearance of any soft tissue plasmacytomas, and (iii) less than 5% plasma MM cells in the bone marrow. International Myeloma Working Group uniform response criteria.
Treatment-Related Mortality (TRM) Between 2 Arms. [ Time Frame: 100 days post treatment ]
Number of Participants That Had Grade 3-4 Toxicities. [ Time Frame: At day 90 post SCT (Stem Cell Transplantation) ]
Overall Survival (OS) [ Time Frame: From time of ASCT to 3 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with multiple myeloma in complete remission (CR), partial remission (PR), or very good partial remission (VGPR), or symptomatic stable disease (no evidence of progression) including patients with light chain MM detected in the serum by free light chain assay.
Patients with non-secretory multiple myeloma [absence of a monoclonal protein (M protein) in serum as measured by electrophoresis (SPEP) and immunofixation (SIFE) and the absence of Bence Jones protein in the urine (UPEP) defined by use of conventional electrophoresis and immunofixation (UIFE) techniques] but with measurable disease on imaging studies like MRI, CT scan or PET scan.
Who have received at least two cycles of initial systemic therapy and are within 2 to 12 months of the first dose. Mobilization therapy is not considered initial therapy.
70 years of age or younger.
Karnofsky performance score 70% or higher.
Cardiac function: left ventricular ejection fraction at rest > 40% within 3 months of registration.
Hepatic function: bilirubin < 2x the upper limit of normal and ALT and AST < 2.5x the upper limit of normal.
Renal function: creatinine clearance of >/= 40 mL/min, estimated or calculated.
Pulmonary function: DLCO, FEV1, FVC >/= 50% of predicted value (corrected for hemoglobin) within 3 months of registration
Signed informed consent form.

Exclusion Criteria:

Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms).
Patients seropositive for the human immunodeficiency virus (HIV).
Patients with history of myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
Patients participating in an investigational new drug protocol within 14 days before enrollment.
Female patients who are pregnant (positive b-HCG) or breastfeeding.
Prior stem cell transplantation allogeneic or autologous.
Prior organ transplant requiring immunosuppressive therapy.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01413178

Locations

Layout table for location information

United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Otsuka Pharmaceutical Development & Commercialization, Inc.

Investigators

Layout table for investigator information

Principal Investigator:	Muzaffar H. Qazilbash, MD	M.D. Anderson Cancer Center

Study Documents (Full-Text)

Documents provided by M.D. Anderson Cancer Center:

Study Protocol and Statistical Analysis Plan [PDF] December 14, 2015

More Information

Additional Information:

University of Texas MD Anderson Cancer Center Website This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22.

Layout table for additonal information

Responsible Party:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT01413178
Other Study ID Numbers:	2010-0071 NCI-2011-02760 ( Registry Identifier: NCI CTRP )
First Posted:	August 10, 2011 Key Record Dates
Results First Posted:	April 21, 2020
Last Update Posted:	April 21, 2020
Last Verified:	April 2020

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by M.D. Anderson Cancer Center:


Myeloma Multiple Myeloma Light chain Multiple Myeloma MM Autologous Hematopoietic Stem Cell Transplantation Busulfan Busulfex Myleran Melphalan	Alkeran G-CSF Filgrastim NeupogenTM Questionnaire Survey Quality of Life QOL

Additional relevant MeSH terms:

Layout table for MeSH terms

Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders	Immunoproliferative Disorders Immune System Diseases Melphalan Busulfan Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs

To Top